COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF …
R Dummer, KT Flaherty, C Robert, A Arance… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits
on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the …
on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the …
[HTML][HTML] Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: A mixed-methods …
Background Immune checkpoint inhibitors (ICI) and targeted therapies (TT) have
significantly improved disease control and survival in people with stage III and IV cutaneous …
significantly improved disease control and survival in people with stage III and IV cutaneous …
Theranostic Activity of Ceria-Based Nanoparticles toward Parental and Metastatic Melanoma: 2D vs 3D Models
The time interval between the diagnosis of tumor in a patient and the initiation of treatment
plays a key role in determining the survival rates. Consequently, theranostics, which is a …
plays a key role in determining the survival rates. Consequently, theranostics, which is a …
The benefit of early‐stage diagnosis: A registry‐based survey evaluating the quality of life in patients with melanoma
JN Young, K Griffith‐Bauer, E Hill… - Skin Health and …, 2023 - Wiley Online Library
Background The morbidity associated with advanced stage melanoma is an important
consideration in the dialog surrounding early detection and overdiagnosis. Few studies …
consideration in the dialog surrounding early detection and overdiagnosis. Few studies …
Surgery, limb edema and health-related quality of life: a prospective follow-up study on patients with cutaneous malignant melanoma
P Heino, P Mylläri, T Jahkola, ML Luoma… - Anticancer …, 2022 - ar.iiarjournals.org
Abstract Background/Aim: The latest developments in oncological therapies for malignant
melanoma, and the discovery that complete lymph node dissection offers no survival benefit …
melanoma, and the discovery that complete lymph node dissection offers no survival benefit …
Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III …
PA Ascierto, R Dummer, HJ Gogas, A Arance… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE In COLUMBUS part 1, patients with advanced BRAF V600-mutant melanoma
were randomly assigned 1: 1: 1 to encorafenib 450 mg once daily plus binimetinib 45 mg …
were randomly assigned 1: 1: 1 to encorafenib 450 mg once daily plus binimetinib 45 mg …
[HTML][HTML] Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module
MD Egeler, M van Leeuwen, J Lai-Kwon… - European Journal of …, 2024 - Elsevier
Aims We aimed to develop a European Organization for Research and Treatment of Cancer
(EORTC) Quality of Life (QoL) module tailored for patients with advanced (resectable or …
(EORTC) Quality of Life (QoL) module tailored for patients with advanced (resectable or …
[PDF][PDF] Előrelépések melanomában
G Liszkay - 2023 - real-d.mtak.hu
• A melanoma a világ fehérbőrű népességének megbetegedése, évente több tízezer ember
halálát okozza. Korai stádiumban felfedezve sebészi eltávolítással maradéktalanul …
halálát okozza. Korai stádiumban felfedezve sebészi eltávolítással maradéktalanul …
[PDF][PDF] Allegato A al Decreto n. 116 del 14 OTT. 2021 pag.
R del Veneto - farmindustria.it
I documenti di indirizzo regionali per l'impiego dei farmaci sono elaborati da gruppi di lavoro
multidisciplinari (medici, farmacologi, farmacisti, economisti, esperti di organizzazione …
multidisciplinari (medici, farmacologi, farmacisti, economisti, esperti di organizzazione …
[HTML][HTML] Update ADO 2022: BRAF-/MEK-Inhibitor-Kombinationstherapien beim malignen Melanom
LS mehr zu diesem Thema - journalonko.de
09. November 2022 Update ADO 2022: BRAF-/MEK-Inhibitor-Kombinationstherapien beim
malignen Melanom© lavizzara-stock. adobe. com Patient: innen mit einem malignen …
malignen Melanom© lavizzara-stock. adobe. com Patient: innen mit einem malignen …